JP2002518321A - エネルギーをインビボで増加させるための組成物 - Google Patents

エネルギーをインビボで増加させるための組成物

Info

Publication number
JP2002518321A
JP2002518321A JP2000554356A JP2000554356A JP2002518321A JP 2002518321 A JP2002518321 A JP 2002518321A JP 2000554356 A JP2000554356 A JP 2000554356A JP 2000554356 A JP2000554356 A JP 2000554356A JP 2002518321 A JP2002518321 A JP 2002518321A
Authority
JP
Japan
Prior art keywords
ribose
pentose
mammal
atp
energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518321A5 (https=
Inventor
サイア，ジョン セント
エー． ジョンソン，クラレンス
Original Assignee
バイオエナジー インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエナジー インコーポレイティド filed Critical バイオエナジー インコーポレイティド
Publication of JP2002518321A publication Critical patent/JP2002518321A/ja
Publication of JP2002518321A5 publication Critical patent/JP2002518321A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000554356A 1998-06-19 1999-06-17 エネルギーをインビボで増加させるための組成物 Pending JP2002518321A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9000198P 1998-06-19 1998-06-19
US60/090,001 1998-06-19
US09/290,789 US6159942A (en) 1998-06-19 1999-04-12 Compositions for increasing energy in vivo
US09/290,789 1999-04-12
PCT/US1999/013720 WO1999065476A2 (en) 1998-06-19 1999-06-17 COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010089732A Division JP2010168394A (ja) 1998-06-19 2010-04-08 エネルギーをインビボで増加させるための組成物
JP2013162441A Division JP2013237697A (ja) 1998-06-19 2013-08-05 エネルギーをインビボで増加させるための組成物

Publications (2)

Publication Number Publication Date
JP2002518321A true JP2002518321A (ja) 2002-06-25
JP2002518321A5 JP2002518321A5 (https=) 2012-05-17

Family

ID=26781174

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000554356A Pending JP2002518321A (ja) 1998-06-19 1999-06-17 エネルギーをインビボで増加させるための組成物
JP2010089732A Pending JP2010168394A (ja) 1998-06-19 2010-04-08 エネルギーをインビボで増加させるための組成物
JP2013162441A Pending JP2013237697A (ja) 1998-06-19 2013-08-05 エネルギーをインビボで増加させるための組成物
JP2013229436A Pending JP2014043453A (ja) 1998-06-19 2013-11-05 エネルギーをインビボで増加させるための組成物
JP2016089312A Pending JP2016153421A (ja) 1998-06-19 2016-04-27 エネルギーをインビボで増加させるための組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010089732A Pending JP2010168394A (ja) 1998-06-19 2010-04-08 エネルギーをインビボで増加させるための組成物
JP2013162441A Pending JP2013237697A (ja) 1998-06-19 2013-08-05 エネルギーをインビボで増加させるための組成物
JP2013229436A Pending JP2014043453A (ja) 1998-06-19 2013-11-05 エネルギーをインビボで増加させるための組成物
JP2016089312A Pending JP2016153421A (ja) 1998-06-19 2016-04-27 エネルギーをインビボで増加させるための組成物

Country Status (10)

Country Link
US (1) US6159942A (https=)
EP (1) EP1087779B1 (https=)
JP (5) JP2002518321A (https=)
CN (1) CN1306431A (https=)
AT (1) ATE534393T1 (https=)
AU (1) AU4575299A (https=)
CA (1) CA2334415C (https=)
ES (1) ES2374260T3 (https=)
NZ (1) NZ508478A (https=)
WO (1) WO1999065476A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
JP2012500261A (ja) * 2008-08-20 2012-01-05 バイオエナジー インコーポレイティド 疲労した対象のためのｄ−リボースの使用
JP2017537079A (ja) * 2014-11-03 2017-12-14 バイオエナジー ライフ サイエンス，インコーポレイティド 身体的ストレスへの適応を強化するためのｄ−リボースの使用
WO2023135827A1 (ja) * 2022-01-13 2023-07-20 ＮｅＳＡ合同会社 神経変性疾患の進行遅延及び防御剤

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6159943A (en) * 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6339716B1 (en) * 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6703370B1 (en) * 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
GB2353217B (en) * 1999-10-27 2001-07-18 Bioenergy Inc Use of ribose to treat fibromyalgia
AU1800801A (en) * 1999-11-17 2001-05-30 Eric H. Kuhrts Exercise and muscle enhancement formulations
DE10085291T1 (de) 1999-12-21 2003-05-08 Bioenergy Inc Zusammensetzungen für die Lagerung von Blutplättchen
CA2397707A1 (en) * 2000-01-07 2001-07-19 Susan S. Percival Compositions for enhancing the immune response
WO2001052831A1 (en) 2000-01-20 2001-07-26 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
US6553254B1 (en) * 2000-04-07 2003-04-22 Keith E. Kenyon Combination of non-living-source physical energy and living-source chemical energy to maximize the salvage of ATP
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
IT1317043B1 (it) * 2000-06-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio.
CN1299690C (zh) * 2000-07-28 2007-02-14 生物能量公司 用于提高心血管功能的组合物
US6855727B2 (en) * 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
EP1247525A1 (en) * 2001-04-02 2002-10-09 Bioenergy Inc. Use of a monosaccharide in the manufacture of a medicament against acute mountain sickness
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
GB2381451A (en) * 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US7547450B2 (en) * 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US6838562B2 (en) * 2003-04-01 2005-01-04 Sal Abraham Process for preparing a creatine heterocyclic acid salt and method of use
US8759315B2 (en) * 2003-05-14 2014-06-24 Viacell, Llc Methods for rejuvenating
US7687468B2 (en) * 2003-05-14 2010-03-30 Viacell, LLC. Rejuvenation of stored blood
US20040229205A1 (en) * 2003-05-16 2004-11-18 Ericson Daniel G. Compositions for the storage of platelets
BRPI0506485A (pt) * 2004-01-14 2007-02-13 Bioenergy Inc método para reduzir o tempo de recuperação de um mamìfero submetido a uma anestesia geral, método para aumentar a recuperação de sepsia e uma composição adequada para administração intravenosa
JP4754484B2 (ja) * 2004-03-18 2011-08-24 田辺三菱製薬株式会社 うつ様症状改善剤
EP1786436B1 (en) * 2004-04-29 2012-11-14 RiboCor, Inc. Method for improving ventilatory efficiency
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US7968138B2 (en) * 2004-07-23 2011-06-28 Arnold Nerenberg Food sweetener
US20060029644A1 (en) * 2004-08-06 2006-02-09 Kenyon Keith E In vitro biochemical reactions with free anhydrous D-ribose
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US7566463B2 (en) 2006-05-03 2009-07-28 C. B. Fleet Company Oral rehydration compositions
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
CA2674717C (en) * 2007-01-23 2015-10-13 Bioenergy, Inc. Use of d-ribose to treat cardiac arrhythmias
US20080312169A1 (en) * 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090197819A1 (en) * 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
CN101356971B (zh) * 2007-07-30 2012-11-07 石药集团中奇制药技术（石家庄）有限公司 一种用于抗疲劳耐缺氧的保健食品组合物
CA2853992C (en) 2007-07-31 2020-06-23 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090061016A1 (en) * 2007-09-05 2009-03-05 Selzer Jonathan A Seawater Based Dietary Supplement Product for Energy and Electrolyte Replacement
US20090232750A1 (en) * 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
EP2413942A1 (en) * 2008-04-02 2012-02-08 Bioenergy Inc. Use of ribose in first response to acute myocardial infarction
ES2422596T3 (es) 2008-05-16 2013-09-12 Robert V Kasubick Uso de ribosa en el tratamiento del síndrome de las piernas inquietas
AU2009266869B2 (en) 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
IT1391588B1 (it) * 2008-10-15 2012-01-11 Giellepi Chemicals S P A Composizione sinergica per il recupero e la riduzione del danno ischemico lieve
US8255453B2 (en) 2009-09-14 2012-08-28 International Business Machines Corporation Public BOT management in private networks
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP5823985B2 (ja) 2010-02-16 2015-11-25 ビアセル，リミティド ライアビリティ カンパニー 赤血球を治療するためのアルギニン含有組成物および方法
US20110229871A1 (en) * 2010-02-16 2011-09-22 Ericson Daniel G Nucleoside-containing compositions and methods for treating red blood cells
CN102058045B (zh) * 2010-10-26 2012-09-19 开平牵牛生化制药有限公司 一种用于补充人体能量和恢复疲劳的饮品
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
CA2951567C (en) 2014-06-12 2023-10-31 Lonza, Inc. Method for decreasing skeletal muscle damage and/or oxidative stress in mammals
BR112018012410B1 (pt) 2015-12-18 2022-12-20 Lonza Consumer Health Inc Composição para o aumento da síntese de proteína e/ou força funcional musculares em mamíferos
EP4241838A3 (en) 2016-02-01 2023-12-20 Bioenergy Life Science, Inc. Use of ribose for treatment of subjects having congestive heart failure
CN108433106A (zh) * 2017-11-07 2018-08-24 付少才 一种耐缺氧活性果糖粉(液)组合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6232860A (ja) * 1985-08-06 1987-02-12 Riichiro Yamazaki 健康食品
JPH01175939A (ja) * 1987-12-29 1989-07-12 Roncari Raymond A 細胞内ａｔｐ濃度及び生体活動レベルを増進し且つ創傷修復率を増進するための組成物
JPH02212A (ja) * 1987-10-14 1990-01-05 Takeda Chem Ind Ltd 経口用水性製剤
JPH02211854A (ja) * 1988-07-29 1990-08-23 Univ Florida 運動に対する改良された生理学的応答を達成する為の組成物及び方法
WO1992015311A1 (en) * 1991-03-01 1992-09-17 Depha Team S.R.L. Dietetic or pharmaceutical compositions for the restoration of adenine nucleotide cell content in skeletal and cardiac muscles
WO1994004158A1 (de) * 1992-08-25 1994-03-03 Wolfgang Pliml Verwendung von ribose zur herstellung eines arzneimittels zur behandlung von leistungsschwächen des körpers, insbesondere von organinsuffizienzen
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH07233070A (ja) * 1994-02-23 1995-09-05 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH07236460A (ja) * 1994-02-28 1995-09-12 Haruhiko Sueoka クレアチン飲料とその製造方法
JPH07330584A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH08224073A (ja) * 1995-02-20 1996-09-03 Haruhiko Sueoka クレアチン飲料とその製造方法
WO1997045026A1 (en) * 1996-05-31 1997-12-04 The Howard Foundation Improvements in or relating to compositions containing creatine
US5714515A (en) * 1994-05-09 1998-02-03 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions, method of making and use thereof
JPH10113147A (ja) * 1996-10-08 1998-05-06 Ito Ham Kk 体力増強・疲労回復剤及びそれを用いた食品
DE19650755A1 (de) * 1996-12-06 1998-06-10 Wolfgang Dr Pliml Anwendung von Ribose zur Leistungssteigerung
JPH11103797A (ja) * 1997-07-22 1999-04-20 Cerestar Holding Bv 肉体運動を増強するための飲料

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6049764A (ja) * 1983-08-29 1985-03-19 Ajinomoto Co Inc 食品組成物
JPS6094075A (ja) * 1983-10-31 1985-05-27 Ajinomoto Co Inc 果汁飲料組成物
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4824660A (en) * 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
AU2228888A (en) * 1987-10-14 1989-05-25 Takeda Chemical Industries Ltd. Aqueous pharmaceutical preparation for oral administration
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5114723A (en) * 1990-02-27 1992-05-19 University Of Texas System Board Of Regents Beverage compositions for human consumption
FR2668039B1 (fr) * 1990-10-18 1993-06-25 Pernod Ricard Boisson dietetique destinee a permettre de soutenir l'effort.
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
AU1780395A (en) * 1994-05-02 1995-11-09 Omeara (Proprietary) Limited Amino acid, carnitine and magnesium supplementation
GB9517443D0 (en) * 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US5709971A (en) 1995-06-20 1998-01-20 Eastman Kodak Company Dye imbibition printing blanks with antistatic layer

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6232860A (ja) * 1985-08-06 1987-02-12 Riichiro Yamazaki 健康食品
JPH02212A (ja) * 1987-10-14 1990-01-05 Takeda Chem Ind Ltd 経口用水性製剤
JPH01175939A (ja) * 1987-12-29 1989-07-12 Roncari Raymond A 細胞内ａｔｐ濃度及び生体活動レベルを増進し且つ創傷修復率を増進するための組成物
JPH02211854A (ja) * 1988-07-29 1990-08-23 Univ Florida 運動に対する改良された生理学的応答を達成する為の組成物及び方法
WO1992015311A1 (en) * 1991-03-01 1992-09-17 Depha Team S.R.L. Dietetic or pharmaceutical compositions for the restoration of adenine nucleotide cell content in skeletal and cardiac muscles
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
WO1994004158A1 (de) * 1992-08-25 1994-03-03 Wolfgang Pliml Verwendung von ribose zur herstellung eines arzneimittels zur behandlung von leistungsschwächen des körpers, insbesondere von organinsuffizienzen
JPH07233070A (ja) * 1994-02-23 1995-09-05 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH07236460A (ja) * 1994-02-28 1995-09-12 Haruhiko Sueoka クレアチン飲料とその製造方法
US5714515A (en) * 1994-05-09 1998-02-03 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions, method of making and use thereof
JPH07330584A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH08224073A (ja) * 1995-02-20 1996-09-03 Haruhiko Sueoka クレアチン飲料とその製造方法
WO1997045026A1 (en) * 1996-05-31 1997-12-04 The Howard Foundation Improvements in or relating to compositions containing creatine
JPH10113147A (ja) * 1996-10-08 1998-05-06 Ito Ham Kk 体力増強・疲労回復剤及びそれを用いた食品
DE19650755A1 (de) * 1996-12-06 1998-06-10 Wolfgang Dr Pliml Anwendung von Ribose zur Leistungssteigerung
JPH11103797A (ja) * 1997-07-22 1999-04-20 Cerestar Holding Bv 肉体運動を増強するための飲料

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
JP2012500261A (ja) * 2008-08-20 2012-01-05 バイオエナジー インコーポレイティド 疲労した対象のためのｄ−リボースの使用
JP2016014009A (ja) * 2008-08-20 2016-01-28 バイオエナジー ライフ サイエンス，インコーポレイティド 疲労した対象のためのｄ−リボースの使用
JP2017537079A (ja) * 2014-11-03 2017-12-14 バイオエナジー ライフ サイエンス，インコーポレイティド 身体的ストレスへの適応を強化するためのｄ−リボースの使用
JP2021001224A (ja) * 2014-11-03 2021-01-07 バイオエナジー ライフ サイエンス，インコーポレイティド 身体的ストレスへの適応を強化するためのｄ−リボースの使用
JP2022190163A (ja) * 2014-11-03 2022-12-22 バイオエナジー ライフ サイエンス，インコーポレイティド 身体的ストレスへの適応を強化するためのｄ－リボースの使用
WO2023135827A1 (ja) * 2022-01-13 2023-07-20 ＮｅＳＡ合同会社 神経変性疾患の進行遅延及び防御剤

Also Published As

Publication number Publication date
JP2010168394A (ja) 2010-08-05
JP2013237697A (ja) 2013-11-28
CN1306431A (zh) 2001-08-01
ES2374260T3 (es) 2012-02-15
ATE534393T1 (de) 2011-12-15
WO1999065476A2 (en) 1999-12-23
JP2014043453A (ja) 2014-03-13
JP2016153421A (ja) 2016-08-25
AU4575299A (en) 2000-01-05
EP1087779B1 (en) 2011-11-23
CA2334415C (en) 2004-08-24
US6159942A (en) 2000-12-12
WO1999065476A3 (en) 2000-04-06
CA2334415A1 (en) 1999-12-23
EP1087779A2 (en) 2001-04-04
NZ508478A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
JP2002518321A (ja) エネルギーをインビボで増加させるための組成物
US6534480B2 (en) Compositions for increasing energy in vivo
US6429198B1 (en) Compositions for increasing athletic performance in mammals
Karlic et al. Supplementation of L-carnitine in athletes: does it make sense?
Clarkson Nutrition for improved sports performance: current issues on ergogenic aids
US9572882B2 (en) Compositions and methods for improving cardiovascular function
JP2001517085A (ja) 激しい運動に対する骨格筋の適用を容易するため、および無力症者における疲労に対処するための栄養補助剤
HUE032486T2 (en) An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
JP2003516315A (ja) 筋肉の痙攣及び筋肉痛を予防するためのリボースの利用
KR20110135986A (ko) 당뇨병 요법을 지원하기 위한 α-케토산을 포함하는 식이 보충제
Dodd et al. The role of ribose in human skeletal muscle metabolism
EP1313488A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION
EP1745789A1 (en) Compositions comprising ribose for increasing energy in vivo
Andres et al. A review of creatine supplementation: side effects and improvements in athletic performance
CN101264093B (zh) 用于增加体内能量的组合物
Koivisto The physiology of marathon running
KR100523354B1 (ko) 지구성 운동시 피로억제 및 운동 수행 후 면역기능 향상을위한 약학적 조성물 또는 기능성 식품
Macgregor Metabolic implications of obesity, weight loss and energy expenditure following gastric restrictive surgery
Perez Creatine: Physiology and performance: The health effects of creatine in exercise and human performance
CA2161784A1 (en) Enhancing performance capacity by sparing muscle glycogen with medium chain fatty acids
Braverman The Healing Nutrients Within (Volume 2 of 2)(EasyRead Large Bold Edition)
Volek Creatine supplementation and the strength athlete
MEN OP-PN04 Nutrition/Supplements
Heath Niacin
Powers The effects of creatine supplementation on intracellular and extracellular water content

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111227

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120306

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120321

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130510